| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
IC50: 0.1 μM (RPTPβ/ζ), 0.7 μM (PTP-1B)[1]
Receptor protein tyrosine phosphatase (RPTP)beta/zeta (IC50 ~0.1 microM); also inhibits protein tyrosine phosphatase 1B (PTP-1B, IC50 ~0.7 microM). |
|---|---|
| ln Vitro |
In SH-SY5Y cells, MY33-3 (1 μM; pretreatment for 5 min) inhibits the activation of TrkA and ALK caused by ethanol[1]. MY33-3 (0.1-10 μM; 24 h) suppresses the generation of nitrites and an increase in iNos in BV2 microglial cells caused by LPS[2].
MY33-3 demonstrates potent inhibitory activity against RPTPbeta/zeta with an IC50 of approximately 0.1 microM. It also shows moderate inhibition of PTP-1B (IC50 ~0.7 microM). These activities make it a useful tool for studying tyrosine phosphatase-mediated signaling pathways in vitro. |
| ln Vivo |
When comparing day 2 and day 3, MY33-3 (60 mg/kg; po on days 3 and 4) lowers ethanol intake. On day three, MY33-3 decreases preference for the ethanol solution[1]. The decrease in the discriminating index and reduced motor learning capacity caused by sevoflurane are reversed by MY33-3 (ip)[3].
In vivo, MY33-3 at 60 mg/kg administered orally on days 3 and 4 reduces ethanol consumption in animal models when comparing day 2 with day 3. It also reduces preference for ethanol solution on day 3. Additionally, MY33-3 alleviates sevoflurane-induced neuroinflammation and cognitive dysfunction. |
| Enzyme Assay |
MY33-3 is typically dissolved in DMSO to prepare stock solutions (e.g., 10 mg/mL). For enzyme inhibition assays, the compound is diluted in assay buffer to appropriate concentrations (e.g., 0.01-10 microM). RPTPbeta/zeta or PTP-1B enzyme is incubated with substrate in the presence of MY33-3, and phosphatase activity is measured using a colorimetric or fluorogenic substrate. IC50 values are calculated from dose-response curves.
|
| Cell Assay |
Cell Viability Assay[1]
Cell Types: SH-SY5Y cells Tested Concentrations: 1 μM Incubation Duration:Pretreated for 5 min and co-treated for 15 min Experimental Results: diminished the Ethanol-induced activation of TrkA and ALK. None of the treatments Dramatically changed total TrkA or total ALK protein levels. For cell-based assays, cells are cultured in appropriate media and treated with varying concentrations of MY33-3 (typically 0.1-10 microM) for 24-72 hours. Cell viability may be assessed using MTT or CCK-8 assays. The effects of MY33-3 on neuroinflammation are evaluated by measuring cytokine levels (IL-6, TNF-alpha) via ELISA after induction with sevoflurane or LPS. |
| Animal Protocol |
Animal/Disease Models: Male C57BL/6J mice (8-10 weeks of age) are received two-bottle drinking in the dark (DID) procedure using 20% ethanol[1]
Doses: 60 mg/kg Route of Administration: Po 1 hour before the drinking session in the DID test on days 3 and 4 Experimental Results: decreased ethanol consumption when comparing day 2 with day 3. demonstrated a decreased preference for the ethanol solution. Not affected total fluid consumption. MY33-3 is administered orally or intraperitoneally to rodent models. For ethanol consumption studies, mice receive MY33-3 at 60 mg/kg (p.o.) on days 3 and 4. Ethanol intake and preference are measured using a two-bottle choice paradigm. For neuroinflammation studies, sevoflurane-exposed animals are treated with MY33-3, and cognitive function is assessed using Morris water maze or passive avoidance tests. |
| ADME/Pharmacokinetics |
MY33-3 is orally bioavailable and can be formulated in vehicles such as 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% saline for in vivo administration. Its half-life and other detailed pharmacokinetic parameters have not been extensively reported. It is stable at 4degC when stored as a dry solid.
|
| Toxicity/Toxicokinetics |
Detailed toxicological studies for MY33-3 have not been extensively reported. However, the compound is classified for research use only and is not intended for human therapeutic applications. Standard handling precautions for laboratory chemicals should be followed.
|
| References |
|
| Additional Infomation |
MY33-3 belongs to the bis(trifluoromethylthio)benzylamine chemical class with the formula C16H13F6NS2. It is a research tool for studying RPTPbeta/zeta and PTP-1B in the contexts of ethanol consumption and cognitive dysfunction, as supported by literature references. It is not approved for clinical use.
|
| Molecular Formula |
C16H13F6NS2
|
|---|---|
| Molecular Weight |
397.40
|
| Exact Mass |
397.039
|
| CAS # |
2204280-41-9
|
| Related CAS # |
MY33-3 hydrochloride;2204280-42-0
|
| PubChem CID |
145978898
|
| Appearance |
Off-white to light yellow solid powder
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
25
|
| Complexity |
349
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1(CNCC2=CC=C(SC(F)(F)F)C=C2)=CC=C(SC(F)(F)F)C=C1
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 10 mg/mL (25.16 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5164 mL | 12.5818 mL | 25.1636 mL | |
| 5 mM | 0.5033 mL | 2.5164 mL | 5.0327 mL | |
| 10 mM | 0.2516 mL | 1.2582 mL | 2.5164 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
